← Back to Treatments
🏅 FDA Orphan Designation

Voxzogo 0.4Mg

VOSORITIDE

Manufacturer: BioMarin Pharmaceutical Inc.

Indicated for:
AchondroplasiaAccel.

FDA-Approved Indications (1)

AchondroplasiaAccelerated Approval

VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.

Population: pediatric patients with open epiphyses

Indications & Usage

1 INDICATIONS AND USAGE VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )

💙 Support Programs

View all →
Voxzogo 0.4Mg
BioMarin Pharmaceutical Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.